所有图片(3)
别名:
(S)-5-Amino-5-oxo-2-(2-phenylacetamido)pentanoic acid, N-Phenylacetylglutamine, Phenylacetylglutamine
经验公式（希尔记法）:
C13H16N2O4
推荐产品
生物来源
synthetic
质量水平
等级
research grade
检测方案
≥95%
形式
powder
储存条件
(Store in tight containers in a cool and dry place)
技术
HPLC: suitable
颜色
off-white
InChI
1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19)/t10-/m0/s1
InChI key
JFLIEFSWGNOPJJ-JTQLQIEISA-N
一般描述
Phenylacetyl-L-glutamine is a primary human metabolite formed from phenylacetate in presence of glutamine in the liver. It is also considered as a gut-microbiome derived uremic toxin. Phenylacetyl-L-glutamine urine levels serve as an effective biomarker for the excretion of nitrogenous waste. Also, peripheral artery disease patients exhibit higher circulating concentration of phenylacetyl-L-glutamine, and high plasma phenylacetyl-L-glutamine levels are associated with cardiovascular disease.
应用
Phenylacetyl-ʟ-glutamine is a versatile compound that finds application in microbiome and metabolomics research.
特点和优势
- Ideal for biochemical, microbiome and metabolomics studies
- High quality product for research applications
其他说明
For additional information on our range of Biochemicals, please complete this form.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Lu Dai et al.
Toxins, 12(6) (2020-05-31)
Gut microbial metabolism is not only an important source of uremic toxins but may also help to maintain the vitamin K stores of the host. We hypothesized that sevelamer therapy, a commonly used phosphate binder in patients with end-stage kidney
Sandi M Azab et al.
Journal of clinical medicine, 9(6) (2020-06-21)
Peripheral artery disease (PAD) is characterized by the atherosclerotic narrowing of lower limb vessels, leading to ischemic muscle pain in older persons. Some patients experience progression to advanced chronic limb-threatening ischemia (CLTI) with poor long-term survivorship. Herein, we performed serum
Ina Nemet et al.
Cell, 180(5), 862-877 (2020-03-07)
Using untargeted metabolomics (n = 1,162 subjects), the plasma metabolite (m/z = 265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an independent cohort (n = 4,000 subjects) to be associated with cardiovascular disease (CVD) and incident major adverse cardiovascular events (myocardial infarction
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门